Publications by authors named "V Maquet"

Chitin-glucan (CG) is a new generation of prebiotic. NCFM (NCFM) is a probiotic with the ability to decrease abdominal pain. We evaluate the functional and molecular gastrointestinal responses to a synbiotic administration combining CG and NCFM in a rat model of long-lasting colon hypersensitivity.

View Article and Find Full Text PDF
Article Synopsis
  • IBS is a chronic gastrointestinal disorder marked by abdominal pain and altered bowel habits, with limited first-line treatment options focused on specific symptoms.
  • GASTRAP DIRECT is a new medical formulation combining chitin-glucan and simethicone, aimed at treating gas-related symptoms in IBS patients.
  • In a 4-week trial with 120 IBS patients, 67% reported reduced abdominal pain, along with significant improvements in bloating, distension, and overall quality of life, showing promising efficacy of GASTRAP DIRECT.
View Article and Find Full Text PDF

Background: Irritable bowel syndrome (IBS) is one of the most frequent and debilitating conditions leading to gastroenterological referrals. However, recommended treatments remain limited, yielding only limited therapeutic gains. Chitin-glucan (CG) is a novel dietary prebiotic classically used in humans at a dosage of 1.

View Article and Find Full Text PDF

Chitin-glucan (CG), an insoluble dietary fiber, has been shown to improve cardiometabolic disorders associated with obesity in mice. Its effects in healthy subjects has recently been studied, revealing its interaction with the gut microbiota. In this double-blind, randomized, cross-over, twice 3-week exploratory study, we investigated the impacts of CG on the cardiometabolic profile and gut microbiota composition and functions in 15 subjects at cardiometabolic risk.

View Article and Find Full Text PDF

Background: Current data suggest that dietary fibre (DF) interaction with the gut microbiota largely contributes to their physiological effects. The bacterial fermentation of DF leads to the production of metabolites, most of them are volatile. This study analyzed the breath volatile metabolites (BVM) profile in healthy individuals (n=15) prior and after a 3-week intervention with chitin-glucan (CG, 4.

View Article and Find Full Text PDF